Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)

NCT07350785 | Recruiting

• 1 other identifier: 5570/04-03-2025
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Hip fracture is a common injury in older adults and is often associated with serious complications, longer hospital stays, and increased risk of death. One of the most important causes of poor outcomes after hip fracture surgery is infection, including severe infections such as sepsis. Early identification of patients at higher risk for complications could help improve treatment and survival. This study aims to examine whether a blood test parameter called Monocyte Distribution Width (MDW), along with other commonly used inflammatory markers, can help predict complications and survival in elderly patients with hip fracture. MDW is measured as part of a routine complete blood count and has shown promise in the early detection of infection and systemic inflammation. Approximately 100 patients aged 65 years or older who are admitted to the hospital with a low-energy hip fracture will be included in this study. Blood tests will be performed at hospital admission, after surgery, and at other time points as part of standard clinical care. These tests include routine blood counts and inflammatory markers such as C-reactive protein (CRP), procalcitonin (PCT), antithrombin III, and MDW. No additional invasive procedures are required beyond standard medical care. Researchers will collect information about each patient's medical history, overall health status, and daily activity level before the fracture. Patients will be followed after surgery to assess complications, length of hospital stay, and survival at 1 month, 3 months, and 1 year. The results of this study may help determine whether MDW can be used as a simple and reliable marker to identify patients at higher risk of complications or death after hip fracture. This could support earlier intervention, closer monitoring, and improved care for elderly patients with hip fractures in the future.

Conditions

Sepsis; Osteoporotic Hip Fracture; Hip Fracture

Keywords

Monocyte Distribution Width (MDW); Geriatric Patients; Inflammatory Biomarkers; Postoperative Mortality; Postoperative Morbidity; C-reactive Protein; Procalcitonin; Antithrombin III; Hip Fracture

Outcome Measures

Primary Outcomes (1)

• All-cause mortality

  Assessment of all-cause mortality in geriatric patients with low-energy hip fracture and its association with Monocyte Distribution Width (MDW) values measured at admission and during hospitalization.

  Up to 12 months postoperatively.

Secondary Outcomes (4)

• Postoperative morbidity

  From postoperative day 1 through study completion, an average of 1 year.

• Incidence of sepsis

  From postoperative day 1 through study completion, an average of 1 year.

• Change in Monocyte Distribution Width (MDW) over time

  From hospital admission through hospital discharge, up to 14 days postoperatively.

• Length of hospital stay

  From the date of hospital admission until hospital discharge, assessed up to 30 days.

Study Arms (1)

Geriatric Patients With Hip Fracture

This cohort consists of patients aged 65 years or older who are admitted with a low-energy hip fracture and undergo surgical treatment. All participants receive standard-of-care clinical management according to institutional protocols. No experimental interventions are assigned as part of this study. Clinical data, medical history, and pre-fracture functional status are recorded at baseline. Blood samples are collected as part of routine care at hospital admission, postoperatively, and at discharge to measure complete blood count parameters, including Monocyte Distribution Width (MDW), and other inflammatory markers such as C-reactive protein, procalcitonin, and antithrombin III. Participants are followed postoperatively to assess clinical outcomes, including complications, morbidity, mortality, and health-related quality of life. Comparisons will be performed between subgroups defined by clinical outcomes or biomarker levels.

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population includes approximately 100 geriatric patients aged 65 years and older admitted with low-energy hip fractures and treated surgically at the 2nd Orthopaedic Department of the General Hospital of Attica KAT. Participants undergo routine perioperative evaluation, including demographic and clinical data collection and laboratory assessment of inflammatory biomarkers such as monocyte distribution width (MDW), C-reactive protein, procalcitonin, and antithrombin III. Patients are followed prospectively to evaluate postoperative morbidity and all-cause mortality at 1 month, 3 months, and 12 months following surgery.

You may qualify if:

• Patients aged ≥65 years
• Admission with low-energy hip fracture (femoral neck, intertrochanteric, or subtrochanteric fracture)
• Admission to General Hospital of Attica KAT
• Availability of baseline laboratory measurements, including complete blood count with monocyte distribution width (MDW) and inflammatory biomarkers

You may not qualify if:

• Age \<65 years
• High-energy trauma-related hip fractures
• Pathological fractures

Sponsors & Collaborators

• National and Kapodistrian University of Athens: lead

Study Sites (1)

Laboratory for Research of the Musculoskeletal System

Kifissia, Attica, 14561, Greece

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral venous blood samples

MeSH Terms

Conditions

Sepsis; Hip Fractures

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Femoral Fractures; Fractures, Bone; Wounds and Injuries; Hip Injuries; Leg Injuries

Study Officials

• Efstathios Chronopoulos

  KAT General Hospital, Athens Greece

  STUDY DIRECTOR

Central Study Contacts

Efstathios Chronopoulos

CONTACT

00306944837793; stathi24@yahoo.gr

Lamprini Agapitou

CONTACT

00306943550207; labrini.agapitou@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor in Orthopeadics at National and Kapodistrian University of Athens, Laboratory for Reasearch of the Musculoskeletal System Director

Study Record Dates

• First Submitted: December 21, 2025
• First Posted: January 20, 2026
• Study Start: December 1, 2024
• Primary Completion: March 1, 2026
• Study Completion: March 1, 2026
• Last Updated: January 20, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

GR (1)